Detruzitol is a drug that reduces the tone of the smooth muscles of the urinary tract.
Release form and composition
The dosage form of Detruzitol is coated tablets and hard gelatin capsules with prolonged action.
The composition of the tablets:
- Tolterodine L-tartrate (1 or 2 mg per tablet);
- Excipients: anhydrous colloidal silicon dioxide, titanium dioxide, microcrystalline cellulose, sodium starch glycolate, stearic acid, magnesium stearate, calcium hydrogen phosphate dihydrate, hypromellose.
Detruzitol tablets are packaged in blisters of 14 pcs. or in bottles of 60 pcs.
The composition of the capsules:
- Tolterodine L-tartrate (2 or 4 mg per capsule);
- Additional components: sugar granules (consisting of sucrose and corn starch), hypromellose, and Surelease E-7-19010 (consisting of ethyl cellulose, medium chain triglycerides, oleic acid);
- The composition of the capsule shell: gelatin, indigo carmine, titanium dioxide, iron dye yellow oxide and white Opacode White ink S-1-7085 (including titanium dioxide, propylene glycol, shellac, simethicone).
Detruzitol capsules are packaged in blisters of 7 pieces each, sold in 1, 4, 7, 12 or 40 blisters per pack.
Indications for use
In accordance with the instructions for Detruzitol, the drug is intended for the treatment of diseases involving hyperactivity of the bladder, which is manifested by frequent and sudden (imperative) urge to urinate, increased urination and / or incontinence.
The use of Detruzitol, according to the instructions, is contraindicated in:
- Hypersensitivity to tolterodine or any auxiliary component of the drug;
- Delayed urination;
- Myasthenia gravis;
- Severe ulcerative colitis;
- Megacolone (hypertrophy of the entire colon or some particular part of it);
- Closed-angle glaucoma, resistant to treatment.
Detruzitol may be used, but under constant medical supervision for:
- Renal / hepatic failure;
- Gastrointestinal obstructive disease;
- Severe obstruction of the lower urinary tract;
- Hiatal hernia;
- Conditions involving an increased risk of lowering gastrointestinal motility.
With caution, the drug should also be used in children and adolescents under 18 years of age.
The safety of using Detruzitol during pregnancy has not been established; therefore, the drug can only be prescribed for health when the expected benefits for the future mother outweigh the potential risks to the fetus.
Whether tolterodine is excreted in breast milk has not been precisely established; therefore, it is recommended to stop lactation for the period of treatment.
Dosing and Administration
According to the abstract, Detruzitol should be swallowed whole, squeezed enough water.
The recommended daily intake is 4 mg. In the form of capsules, the drug is taken once a day, and tablets - 2 mg twice a day.
Taking into account the tolerability of Detruzitol, the daily dosage can be reduced to 2 mg (capsules at a time, tablets - 1 mg twice). In such a dose, the medication is prescribed to patients with functional disorders of the liver or kidneys, as well as patients who take ketoconazole or other strong CYP3A4 inhibitors.
The most frequent side effect of the drug is dry mouth.
In less than 10% of cases, the use of Detruzitol is accompanied by:
- Accommodation disturbance;
- Decreased tearing;
- Abdominal pain;
- Visual impairment;
- Increased fatigue;
- General weakness;
- Dry skin;
- Chest pain;
- Weight gain;
In some cases (less than 1% of patients) during the period of Detrusitol use, the following are observed:
- Delayed urination;
- Feeling of palpitations;
- Gastroesophageal reflux;
- Confusion of consciousness;
- Peripheral edema;
- Flushing to the skin of the face;
- Anaphylactic reactions.
Before you assign a patient Detruzitol, it must be examined for the absence of organic causes of imperative and frequent urination.
Detruzitol should not be used simultaneously with anticholinergic drugs, since With this combination, the effect of tolterodine is enhanced, and the risk of undesirable reactions increases.
Detruzitol reduces the effect of cisapride and metoclopramide, its effectiveness is reduced by M-cholinomimetics.
Tolterodine L-tartrate is not pharmacologically compatible with harfarin and oral contraceptives containing levonorgestrel or ethinyl estradiol.
Detruzitol is contraindicated in patients with CYP2D6 deficiency who take strong CYP3A4 inhibitors, including some antifungal drugs (itraconazole, miconazole, and ketoconazole) and macrolide antibacterial agents (clarithromycin, erythromycin). Such combined use can lead to an increase in the concentration of tolterodine in the blood, which is fraught with the development of symptoms of overdose.
Women of childbearing age should be warned that during the period of treatment with this drug should use reliable methods of contraception.
With the same active ingredient are produced drugs Roliten and Urotol.
Analogues of Detruzitol by the similarity of the mechanism of action can be considered Novitropan, Driptan, Spazmeks, Toviaz, Vesicard, Spasmolite, Enablex.
Terms and conditions of storage
Detruzitol belongs to the category of drugs dispensed from pharmacies strictly by prescription prescribed by the attending physician. It should be stored at temperatures up to 25 ºC in a place protected from sunlight. Shelf life of tablets is 3 years, capsules - 2 years.